: Schematic of analysis of AZA-treated cell lines and generation of AIM gene panel. Agilent array data were normalized and analyzed by GSEA. The most enriched GSEA gene sets for each tumor type were intersected to produce 80 common upregulated gene sets, out of which we focused our analysis on the upregulated immune gene sets. This immune signature was applied to primary tumors from publicly available cohorts as well as biopsies from AZA and entinostat trials in breast and colorectal cancer. Figure S5: GSEA analysis of cancer testis antigens shows that the pathway is upregulated (NES > 2.15, FDR < 0.25) by AZA in breast, colorectal, and ovarian cancer cell lines. The colored rectangle corresponding to NES is graded from gray (weak) to orange (strong). Figure S6 : The AIM genes separate lung and melanoma TCGA tumors into distinct clusters. Tumors from The Cancer Genome Atlas (A) non-small cell lung cancers, B) melanomas) cluster into "high" and "low" expressing immune signatures based on AIM gene expression. The bars on the far left show the five sets of AIM genes driving the clustering. The shades of blue and orange bars at the top denote squamous versus adenocarcinoma for lung cancer, (LUAD = adenocarcinoma, LUSC = squamous) and primary tumor (light blue) versus metastasis (dark blue) for melanoma. The heat map shows transcript levels from green (low) to red (high).
